JP2010519181A5 - - Google Patents

Download PDF

Info

Publication number
JP2010519181A5
JP2010519181A5 JP2009548468A JP2009548468A JP2010519181A5 JP 2010519181 A5 JP2010519181 A5 JP 2010519181A5 JP 2009548468 A JP2009548468 A JP 2009548468A JP 2009548468 A JP2009548468 A JP 2009548468A JP 2010519181 A5 JP2010519181 A5 JP 2010519181A5
Authority
JP
Japan
Prior art keywords
substituted
amino
alkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009548468A
Other languages
English (en)
Japanese (ja)
Other versions
JP5461197B2 (ja
JP2010519181A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/052778 external-priority patent/WO2008097835A2/en
Publication of JP2010519181A publication Critical patent/JP2010519181A/ja
Publication of JP2010519181A5 publication Critical patent/JP2010519181A5/ja
Application granted granted Critical
Publication of JP5461197B2 publication Critical patent/JP5461197B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009548468A 2007-02-02 2008-02-01 代謝障害を処置するための組成物および方法 Expired - Fee Related JP5461197B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88799407P 2007-02-02 2007-02-02
US60/887,994 2007-02-02
US1231007P 2007-12-07 2007-12-07
US61/012,310 2007-12-07
PCT/US2008/052778 WO2008097835A2 (en) 2007-02-02 2008-02-01 Compositions and methods for the treatment of metabolic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014005460A Division JP5878937B2 (ja) 2007-02-02 2014-01-15 代謝障害を処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2010519181A JP2010519181A (ja) 2010-06-03
JP2010519181A5 true JP2010519181A5 (enExample) 2012-03-08
JP5461197B2 JP5461197B2 (ja) 2014-04-02

Family

ID=39682342

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009548468A Expired - Fee Related JP5461197B2 (ja) 2007-02-02 2008-02-01 代謝障害を処置するための組成物および方法
JP2014005460A Expired - Fee Related JP5878937B2 (ja) 2007-02-02 2014-01-15 代謝障害を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014005460A Expired - Fee Related JP5878937B2 (ja) 2007-02-02 2014-01-15 代謝障害を処置するための組成物および方法

Country Status (7)

Country Link
US (3) US8207196B2 (enExample)
EP (1) EP2120580B1 (enExample)
JP (2) JP5461197B2 (enExample)
CN (1) CN101674730B (enExample)
AU (1) AU2008214095B2 (enExample)
CA (1) CA2677264C (enExample)
WO (1) WO2008097835A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187485B2 (en) * 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
CA2677264C (en) * 2007-02-02 2021-11-30 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9212179B2 (en) * 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9233941B2 (en) * 2007-02-02 2016-01-12 Baylor College Of Medicine Methods and compositions for the treatment of body weight related disorders
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2391619A1 (en) 2009-01-30 2011-12-07 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
SG10201506238SA (en) 2010-08-11 2015-09-29 Millennium Pharm Inc Heteroaryls And Uses Thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2616441B1 (en) 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridine compounds and the uses thereof
EP2625294A4 (en) * 2010-10-07 2014-03-26 Univ Columbia PROCESS FOR TREATING TUMORS WITH A P53 MUTATION
PE20141044A1 (es) 2010-10-13 2014-09-07 Millennium Pharm Inc Heteroarilos y sus usos
SG192126A1 (en) * 2011-01-25 2013-09-30 Univ Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013110007A1 (en) * 2012-01-18 2013-07-25 The Trustees Of Columbia University In The City Of New York USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION
JP6228198B2 (ja) 2012-06-25 2017-11-08 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 異常な脂質生合成シグナル伝達を有するがんを処置するための組成物および方法
US20140275178A1 (en) * 2013-03-13 2014-09-18 Musc Foundation For Research Development Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders
CN106029072A (zh) * 2013-08-28 2016-10-12 麦迪韦逊技术股份有限公司 杂环化合物和使用方法
JP2016534124A (ja) * 2013-08-29 2016-11-04 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 代謝並びに体重関連疾患の処置のための組成物および方法
JP2017505787A (ja) * 2014-02-14 2017-02-23 ザ ユニバーシティ オブ ブリティッシュ コロンビア 治療薬としてのヒトアンドロゲン受容体ｄｎａ結合ドメイン（ｄｂｄ）化合物およびそれらを使用する方法
US9873689B2 (en) 2014-11-07 2018-01-23 Fgh Biotech, Inc. Synthesis of fatostatin based polycyclic compounds
US10328064B2 (en) 2014-12-23 2019-06-25 Fgh Biotech, Inc. Compositions of fatostatin based heterocyclic compounds and uses thereof
JP6483272B2 (ja) * 2015-02-17 2019-03-13 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ 白色脂肪組織の褐色化を誘導するための化合物および方法
JP2018507234A (ja) 2015-03-04 2018-03-15 メディベイション テクノロジーズ エルエルシー 肝臓線維症、コレステロールの上昇およびインスリン抵抗性を処置する際における使用のためのｓｒｅｂｐ遮断薬
WO2016141258A1 (en) 2015-03-04 2016-09-09 Medivation Technologies, Inc. Sterol regulatory element-binding proteins (srebps) inhibitors
HK1245664B (en) * 2015-05-29 2020-06-26 Changiz Taghibiglou Polypeptides to treat skin conditions associated with overproduction of sebum
EP3370714A4 (en) * 2015-11-06 2019-07-03 The Children's Hospital of Philadelphia COMPOSITIONS AND METHOD FOR THE TREATMENT OF FATTY ACIDIFICATION DISORDERS
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
CN109476635B (zh) 2016-04-29 2021-07-13 Fgh生物科技公司 用于治疗疾病的二取代吡唑类化合物
AU2017323521B9 (en) * 2016-09-07 2022-02-17 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
KR101869308B1 (ko) * 2017-02-28 2018-06-20 대구가톨릭대학교산학협력단 Srebp-1 디코이 올리고디옥시뉴클레오티드 및 이를 유효성분으로 함유하는 지방간 질환의 예방 또는 치료용 약학 조성물
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
WO2019148125A1 (en) 2018-01-29 2019-08-01 Capulus Therapeutics, Llc Srebp inhibitors comprising a 6-membered central ring
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
CA3127828A1 (en) * 2019-01-28 2020-08-06 Capulus Therapeutics, Llc Srebp inhibitors comprising a thiophene central ring
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
WO2021035031A1 (en) * 2019-08-21 2021-02-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of phospholipid synthesis and methods of use
EP4096659A4 (en) * 2020-01-27 2023-10-18 Capulus Therapeutics, LLC SREBP INHIBITORS COMPRISING A THIOPHENIC RING
US12186297B2 (en) * 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
TW202413642A (zh) * 2022-05-25 2024-04-01 美商安進公司 用於抑制ｓｃａｐ表現的ｒｎａｉ構建體及其使用方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791200A (en) 1987-06-22 1988-12-13 Ortho Pharmaceutical Corporation 2-substituted-4-aryl-substituted thiazoles
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
TW311136B (enExample) 1990-11-30 1997-07-21 Otsuka Pharma Co Ltd
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH04282326A (ja) * 1991-03-08 1992-10-07 Yuki Gosei Kogyo Co Ltd 非対称な三環系化合物の製造法
JPH06508371A (ja) 1991-06-21 1994-09-22 ユニバーシティー オブ シンシナティ 経口投与できる治療用タンパク質及びその製法
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
MY128323A (en) 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
JPH1179993A (ja) 1997-09-05 1999-03-23 Sumitomo Pharmaceut Co Ltd 免疫抑制剤
JPH11186479A (ja) 1997-12-22 1999-07-09 Toyo Commun Equip Co Ltd 放熱板付き表面実装部品
JP2000080086A (ja) * 1998-07-01 2000-03-21 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
IL140422A0 (en) 1998-07-01 2002-02-10 Retinoid Related Receptor Func Retinoid-related receptor function regulating agent
GB9916757D0 (en) 1999-07-17 1999-09-15 Glaxo Group Ltd Method
US6537514B1 (en) 1999-10-26 2003-03-25 Praxair Technology, Inc. Method and apparatus for producing carbon dioxide
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
ATE440096T1 (de) 2000-12-08 2009-09-15 Takeda Pharmaceutical Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendung
EP1379525B1 (en) * 2001-02-21 2007-10-10 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US7153889B2 (en) 2002-11-12 2006-12-26 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
US20040248957A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
BRPI0514017A (pt) 2004-08-03 2008-05-27 Wyeth Corp indazóis úteis no tratamento de doenças cardiovasculares
AR051597A1 (es) 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno
WO2006080406A1 (ja) * 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. 三環性化合物
WO2006133559A1 (en) * 2005-06-14 2006-12-21 Merck Frosst Canada Ltd. Reversible inhibitors of monoamine oxidase a and b
WO2007001973A1 (en) * 2005-06-28 2007-01-04 Astrazeneca Ab New use
EP1962892A4 (en) * 2005-11-22 2011-10-12 Univ South Florida INHIBITION OF CELL PROLIFERATION
CA2677264C (en) * 2007-02-02 2021-11-30 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
JP6166266B2 (ja) * 2011-10-04 2017-07-19 ダウ コーニング コーポレーションＤｏｗ Ｃｏｒｎｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ 鉄（ｉｉｉ）含有の錯体及び縮合反応触媒、該触媒を調製する方法、並びに該触媒を含む組成物

Similar Documents

Publication Publication Date Title
JP2010519181A5 (enExample)
KR101179087B1 (ko) 인간 단백질 티로신 포스파타아제 억제제 및 이용 방법
RU2461551C2 (ru) Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
RU2009118602A (ru) Производное индола
JP2009513563A5 (enExample)
AU2007265453A2 (en) Human protein tyrosine phosphatase inhibitors and methods of use
JP2010506825A5 (enExample)
JP2004534035A5 (enExample)
RU2013143028A (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
WO2007123269A1 (ja) アゾールカルボキサミド誘導体
AU2006343359A1 (en) Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
JP2006516251A5 (enExample)
RU2010142229A (ru) Производное циклопентилакриламида
JP2016534124A5 (enExample)
KR20080034436A (ko) 암 치료에 사용되는 티아졸 유도체 및 유사체
RU2004129285A (ru) Производные тиазола в качестве антагонистов рецептора npy
RU2015126293A (ru) Производные тиазола в качестве ингибиторов тирозинкиназы брутона
CN101237866A (zh) 噻唑类衍生物和类似物在游离脂肪酸引起的疾病中的应用
RU2435763C2 (ru) Ингибиторы тирозинфосфатазы белка человека и способы применения
JP2004513923A5 (enExample)
WO2006125285B1 (en) Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
HK1129387B (en) Human protein-tyrosine phosphatase inhibitors and methods of use
HRP20110716T1 (hr) Aril dikarboksamidi